BNP Paribas Financial Markets
VINC

BNP Paribas Financial Markets’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

BNP Paribas Financial Markets’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30
Closed -$824 – 4726
2022
Q3 		$824 Buy
+30
New +$863 ﹤0.01% 4459

Other funds holding VINC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BNP Paribas Financial Markets's VINC Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2022, closing a stake of 30 shares — an estimated $824 sold.

BNP Paribas Financial Markets first reported a position in VINC in Q3 2022 and held it in 1 quarter. The position peaked at $824 in Q3 2022. 35 funds tracked by Wall St. Rank hold VINC as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 30 Vincerx Pharma, Inc. Common Stock shares in Q4 2022, an estimated $824.
  • BNP Paribas Financial Markets first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • BNP Paribas Financial Markets's Vincerx Pharma, Inc. Common Stock position peaked at $824 in Q3 2022.
  • 35 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.